Plymouth Buys iSOFT Business Intelligence to Raise Labs Performance

iSOFTiSOFT, a CSC company, has agreed a deal with Plymouth Hospitals NHS Trust for a business intelligence tool to boost performance across its busy laboratory departments to deliver continuous service improvements.

Drawing information from the iSOFT laboratory system at Plymouth, the new solution will provide a dashboard to monitor key performance indicators in real time. This includes the turnaround times of test samples to guarantee targets are met. The trust faces local and national NHS targets for A&E specimens for instance, plus contractual targets for commercial treatment centres and private healthcare firms.

"The iSOFT solution will allow us to proactively manage specimens to identify potential breaches in turnaround times before they become critical," said Adrian Heathcote, the trust's pathology IT manager. "This represents a fundamental shift in ethos.

"It is impossible to monitor targets in real time using the data extract tools commonly found in pathology departments, so breaches only become apparent after the event," he added. "The solution will help mitigate risk and is an additional tool to help us continue with our other customer-focused service improvements."

A second phase will see iSOFT's laboratory business intelligence solution used to optimise workflows and improve performance. This includes plans to examine demand to ensure the right people and skills are in place at peak times and to pinpoint bottlenecks.

The solution will used across all three laboratories at Plymouth's Derriford Hospital and across all laboratory disciplines, including histopathology, microbiology, haematology, and clinical biochemistry. The trust's Pathology Directorate employs 257 staff and conducts 6.5 million tests on 1.3 million specimens a year.

"Seventy to eighty percent of diagnoses now rely on pathology tests and the pressure on laboratory services will only intensify," said Adrian Stevens, managing director of iSOFT's UK business. "Our solution gives pathology departments the means to remove inefficiencies and find savings.

"As an early adopter, we will work closely with Plymouth to further shape the product to meet specific NHS needs."

Related news articles:

About CSC
CSC is a global leader in providing technology-enabled business solutions and services. Headquartered in Falls Church, Va., CSC has approximately 97,000 employees and reported revenue of $16.2 billion for the 12 months ended September 30, 2011.

Most Popular Now

Study Sheds Light on Hurdles Faced in Tr…

Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools...

Using Deep Learning for Precision Cancer…

Altuna Akalin and his team at the Max Delbrück Center have developed a new tool to more precisely guide cancer treatment. Described in a paper published in Nature Communications, the...

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...